Perioperative Cancer Cell Dissemination and Systemic Immune Suppression in Resectable Ductal Pancreatic Adenocarcinoma

This study has been completed.

Sponsor:

Collaborators:

FWO Fonds voor Wetenschappelijk Onderzoek (FWO), Vlaanderen, Belgium

Agentschap voor Innovatie door Wetenschap en Technologie

Information provided by:

Katholieke Universiteit Leuven

ClinicalTrials.gov Identifier:

NCT00495924

First received: July 2, 2007

Last updated: July 7, 2009

Last verified: July 2009

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	October 2008
Estimated Primary Completion Date:	No date given

No publications provided by Katholieke Universiteit Leuven

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Sergeant G, van Eijsden R, Roskams T, Van Duppen V, Topal B. Pancreatic cancer circulating tumour cells express a cell motility gene signature that predicts survival after surgery. BMC Cancer. 2012 Nov 16;12:527. doi: 10.1186/1471-2407-12-527.

To Top